High-dose immunoglobulin therapy as an immunomodulatory treatment of rheumatoid arthritis
Corresponding Author
Bruno Tumiati MD
Assistant Professor, Second Department of Medicine, Rheumatologic Section
Second Department of Medicine, Rheumatologic Section, and the United Laboratories, Ospedale S. Maria Nuova, Reggio Emilia, Italy
Second Department of Medicine, Ospedale S. Maria Nuova, Viale Umberto I, 50, 42100 Reggio Emilia, ItalySearch for more papers by this authorPatrizia Casoli MD
Assistant, Second Department of Medicine, Rheumatologic Section
Second Department of Medicine, Rheumatologic Section, and the United Laboratories, Ospedale S. Maria Nuova, Reggio Emilia, Italy
Search for more papers by this authorMaura Veneziani MD
Assistant, Second Department of Medicine, Rheumatologic Section
Second Department of Medicine, Rheumatologic Section, and the United Laboratories, Ospedale S. Maria Nuova, Reggio Emilia, Italy
Search for more papers by this authorGabriele Rinaldi MD
Assistant, United Laboratories
Second Department of Medicine, Rheumatologic Section, and the United Laboratories, Ospedale S. Maria Nuova, Reggio Emilia, Italy
Search for more papers by this authorCorresponding Author
Bruno Tumiati MD
Assistant Professor, Second Department of Medicine, Rheumatologic Section
Second Department of Medicine, Rheumatologic Section, and the United Laboratories, Ospedale S. Maria Nuova, Reggio Emilia, Italy
Second Department of Medicine, Ospedale S. Maria Nuova, Viale Umberto I, 50, 42100 Reggio Emilia, ItalySearch for more papers by this authorPatrizia Casoli MD
Assistant, Second Department of Medicine, Rheumatologic Section
Second Department of Medicine, Rheumatologic Section, and the United Laboratories, Ospedale S. Maria Nuova, Reggio Emilia, Italy
Search for more papers by this authorMaura Veneziani MD
Assistant, Second Department of Medicine, Rheumatologic Section
Second Department of Medicine, Rheumatologic Section, and the United Laboratories, Ospedale S. Maria Nuova, Reggio Emilia, Italy
Search for more papers by this authorGabriele Rinaldi MD
Assistant, United Laboratories
Second Department of Medicine, Rheumatologic Section, and the United Laboratories, Ospedale S. Maria Nuova, Reggio Emilia, Italy
Search for more papers by this authorAbstract
Objective. To investigate the efficacy of high-dose intravenous immunoglobulin (IVIg) in the treatment of refractory rheumatoid arthritis (RA).
Methods. Ten patients with active, severe RA that was unresponsive to first- and second-line agents were administered IVIg monthly, for 6 months.
Results. Following IVIg treatment, there was significant improvement in both subjective and objective parameters of disease activity in all 9 patients who completed the protocol. This improvement was noted to occur as early as after the second infusion of IVIg. After discontinuation of the treatment, all patients had a relapse of the disease within a few weeks.
Conclusion. Since the reduction in clinical activity paralleled a decrease in the CD4+CDw29+: CD4+CD45RA+ cell ratio, some of the therapeutic benefits associated with IVIg may be due to a direct influence on the CD4+CD45RA+ subset. Although the possibility of carrying out further controlled studies on a larger scale is limited by the high cost of the treatment, IVIg appears to be an effective therapy for refractory RA.
References
- 1
Imbach P,
Wagner HP,
Berchtold WP,
Gaedicke G,
Hirt A,
Joller P,
Mueller-Eckhardt C,
Muller B,
Rossi E,
Baranown S:
Intravenous immunoglobulin versus oral corticosteroids in acute thrombocytopenic purpura in childhood.
Lancet
11: 464–468,
1985
10.1016/S0140-6736(85)90400-3 Google Scholar
- 2 Newburger JW, Takahasci M, Burns J: The treatment of Kawasaki syndrome with intravenous gammaglobulin. N Engl J Med 315: 341–347, 1986
- 3 Hilgartner MW, Bussel J: Use of intravenous gamma globulin for the treatment of autoimmune neutropenia of childhood and autoimmune hemolytic anemia. Am J Med 83: 25–30, 1987
- 4 Heinze E, Thon A, Vetter V: Gammaglobulin therapy in 6 newly diagnosed diabetic children. Acta Paediatr Scand 74: 295–299, 1985
- 5 Corvetta A, Della Bitta R, Gabrielli A, Spaeth PJ, Danieli G: Use of high dose intravenous immunoglobulin in systemic lupus erythematosus: report of 3 cases. Clin Exp Rheumatol 7: 295–300, 1989
- 6 Ching-Yuang L, Hey-Chi H, Hung C: Improvement of histological and immunological change in steroid and immunosuppressive drug-resistant lupus nephritis by high-dose intravenous gamma globulin. Nephron 53: 303–310, 1989
- 7 Godard W, Roujeau JC, Guillot B, Andre C, Rifle G: Bullous pemphigoid and intravenous gammaglobulin. Ann Intern Med 103: 964–965, 1985
- 8 Carreras LO, Perez GN, Vega HR, Casavilla F: Lupus anticoagulant and recurrent fetal loss: successful treatment with gammaglobulin. Lancet II: 393–394, 1988
- 9
Fathe-Maghadam A,
Wick M,
Besinger U,
Gevrsen RG:
High dose intravenous gammaglobulin for myasthenia gravis.
Lancet
1: 848–849,
1984
10.1016/S0140-6736(84)92294-3 Google Scholar
- 10 Cherin P, Herson S, Wechsler B, Piette JC, Bletry O, Coutellier A, Ziza JZ, Godeau P: Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med 91: 162–168, 1991
- 11 Lang BA, Laxter RM, Murphy G, Silverman ED, Roifman CM: Treatment of dermatomyositis with intravenous gammaglobulin. Am J Med 91: 169–172, 1991
- 12 Silverman ED, Laxer RM, Greenwald M, Gelfand E, Shore A, Stein LD, Roifman CM: Intravenous gamma globulin therapy in systemic juvenile rheumatoid arthritis. Arthritis Rheum 33: 1015–1022, 1990
- 13 Prieur AM, Adleff A, Debre M, Boulate P, Griscelli C: High dose immunoglobulin therapy in severe juvenile chronic arthritis: long-term follow-up in 16 patients. Clin Exp Rheumatol 8: 603–609, 1990
- 14 Becker H, Mitropoulou G, Helmke K.: Immunomodulating therapy of rheumatoid arthritis by high-dose intravenous immunoglobulin. Klin Wochenschr 67: 286–290, 1989
- 15 Combe B, Cosso B, Clot J, Bonneau M, Sany J: Human placenta-eluted gammaglobulin in immunomodulating treatment of rheumatoid arthritis. Am J Med 78: 920–928, 1985
- 16 Tumiati B, Bellelli A, Veneziani M, Castellini G: Use of high-dose immunoglobulin in rheumatoid arthritis. Prog Rheumatol 4: 39–45, 1990
- 17 Morimoto C, Letvin NL, Distaso JA, Aldrich WR, Schlossman SF: The isolation and characterization of the human suppressor inducer T cell subset. J Immunol 134: 1508–1515, 1985
- 18 Morimoto C, Letvin NL, Boyd AW, Hagan M, Brown HM, Kornacki MM, Schlossman SF: The isolation and characterization of the human helper inducer T cell subset. J Immunol 134: 3762–3769, 1985
- 19 Emery P, Gentry KC, Mackay IR, Muirden KD, Rowley M: Deficiency of the suppressor inducer subset of T lymphocytes in rheumatoid arthritis. Arthritis Rheum 30: 849–856, 1987
- 20 Pitzalis C, Kingsley G, Murphy J, Panayi G: Abnormal distribution of the helper inducer and the suppressor inducer T lymphocyte subsets in the rheumatoid joint. Clin Immunol Immunopathol 45: 252–258, 1987
- 21 Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315–324, 1988
- 22 Ritchie DM, Boyle JA, McInnes JM, Jasani MK, Dalakos TG, Grieveson P, Buchanan WW: Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 37: 393–406, 1968
- 23 Steinbrocker O, Traeger CH, Batterman RC: Therapeutic criteria in rheumatoid arthritis. JAMA 140: 659–662, 1949
- 24 Lee P, Jasani MK, Dick WC, Buchanan WW: Evaluation of a functional index in rheumatoid arthritis. Scand J Rheumatol 2: 71–77, 1973
- 25 Kimberly RP, Salmon JE, Bussel JB, Crown MK, Hilgartner MW: Modulation of mononuclear phagocyte function by intravenous gammaglobulin. J Immunol 132: 745, 1984
- 26 Kurlander RJ, Hall J: Comparison of intravenous gammaglobulin and a monoclonal anti-Fc receptor antibody as inhibitors of immune complexes in vivo in mice. J Clin Invest 77: 2010–2018, 1986
- 27 Mannhalter JW, Ahmad R, Wolf HM, Eibl M: Effect of polymeric IgG on human monocyte functions. Int Arch Allergy Appl Immunol 82: 159–167, 1987
- 28 Shimozato TF, Iwata M, Kawada H, Tamura N: Human immunoglobulin preparation for intravenous use induces elevation of cellular cyclic adenosine 3′:5′-monophosphate levels, resulting in suppression of tumor necrosis factor alpha and interleukin 1 production. Immunology 72: 497–501, 1991
- 29 Tankersley DL, Preston MS, Finlayson JS: Immunoglobulin G dimer: an idiotype-anti-idiotype complex. Mol Immunol 25: 41–48, 1988
- 30 Kaveri SV, Dietrich G, Hurez V, Kazatchkine MD: Intravenous immunoglobulins (IVIg) in the treatment of autoimmune disease. Clin Exp Immunol 86: 192–199, 1991
- 31 Stohl W, Mayer L: Inhibition of T cell-dependent human B cell proliferation and B cell differentiation by poly-specific monomeric IgG. Clin Exp Immunol 70: 649–657, 1987
- 32 Tsubakio T, Kurata Y, Katagiri S, Kanakura Y Tamaki T, Kuyama J, Kanayama Y, Yonezawa T, TTarui S: Alteration of T cell subsets and gammaglobulin therapy in patients with idiopathic thrombocytopenic purpura Clin Exp Immunol 53: 697–702, 1983
- 33 Sato K, Miyasaka N, Yamaoka K, Okuda M, Yata J Nishioka K: Quantitative defect of CD4+2H4+ cells in systemic lupus erythematosus and Sjögren's syndrome Arthritis Rheum 30: 1407–1411, 1987
- 34 Gerli R, Bertotto A, Rambotti P, Barbieri P, Ciompi ML, Bombardieri S: T cell immunoregulation in rheumatoid arthritis (letter). Arthritis Rheum 31: 1075– 1076, 1988
